Paolo Bironzo

4.7k total citations
100 papers, 1.2k citations indexed

About

Paolo Bironzo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Paolo Bironzo has authored 100 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Paolo Bironzo's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Paolo Bironzo is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Paolo Bironzo collaborates with scholars based in Italy, France and United States. Paolo Bironzo's co-authors include Giorgio V. Scagliotti, Massimo Di Maïo, Silvia Novello, Luisella Righi, Francesca Vignani, Valentina Bertaglia, Marcello Tucci, Consuelo Buttigliero, Francesco Passiglia and Marco Volante and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Paolo Bironzo

94 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paolo Bironzo Italy 18 637 505 334 191 111 100 1.2k
Morena Fasano Italy 20 535 0.8× 680 1.3× 605 1.8× 244 1.3× 92 0.8× 63 1.4k
Mimma Rizzo Italy 17 696 1.1× 428 0.8× 484 1.4× 333 1.7× 61 0.5× 78 1.1k
Umang Swami United States 21 634 1.0× 727 1.4× 468 1.4× 282 1.5× 176 1.6× 173 1.6k
Sung Hoon Sim South Korea 18 325 0.5× 493 1.0× 243 0.7× 230 1.2× 75 0.7× 81 1.0k
Judit Moldvay Hungary 20 599 0.9× 735 1.5× 447 1.3× 247 1.3× 92 0.8× 79 1.3k
Deepak Kilari United States 18 466 0.7× 558 1.1× 300 0.9× 281 1.5× 126 1.1× 110 1.1k
Sander Bins Netherlands 17 324 0.5× 688 1.4× 376 1.1× 117 0.6× 150 1.4× 59 1.2k
Ion Cotarla United States 10 347 0.5× 563 1.1× 384 1.1× 183 1.0× 63 0.6× 19 1.1k
Dale R. Shepard United States 17 470 0.7× 478 0.9× 419 1.3× 258 1.4× 107 1.0× 75 1.2k
Dipesh Uprety United States 15 377 0.6× 484 1.0× 313 0.9× 128 0.7× 64 0.6× 71 1.0k

Countries citing papers authored by Paolo Bironzo

Since Specialization
Citations

This map shows the geographic impact of Paolo Bironzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Bironzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Bironzo more than expected).

Fields of papers citing papers by Paolo Bironzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Bironzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Bironzo. The network helps show where Paolo Bironzo may publish in the future.

Co-authorship network of co-authors of Paolo Bironzo

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Bironzo. A scholar is included among the top collaborators of Paolo Bironzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Bironzo. Paolo Bironzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations
2.
Capelletto, Enrica, Fabrizio Tabbò, Francesco Leo, et al.. (2025). Therapeutic management of patients with advanced thymic malignancies: A review for clinicians. Lung Cancer. 204. 108554–108554.
3.
Balbi, Maurizio, Anna Caroli, Paolo Bironzo, et al.. (2024). CT-Guided Core Needle Biopsy of Pulmonary Lesions Associated With Cystic Airspaces: A Case-Control Study. American Journal of Roentgenology. 223(1). e2431042–e2431042. 3 indexed citations
4.
Masip, J. Remon, Paolo Bironzo, N. Girard, et al.. (2024). LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Annals of Oncology. 35. S1270–S1270. 3 indexed citations
5.
6.
Charpidou, Andriani, Grigoris Gerotziafas, Sanjay Popat, et al.. (2024). Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade. Cancers. 16(2). 450–450. 3 indexed citations
7.
Cerbone, Linda, Sara Delfanti, Paola Barbieri, et al.. (2024). Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases. PubMed. 14(1). 2424133–2424133. 1 indexed citations
8.
Tagliamento, Marco, Massimo Di Maïo, Jordi Remón, et al.. (2023). Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(1). 166–172. 8 indexed citations
9.
Levis, Mario, Cristina Mantovani, Paolo Bironzo, et al.. (2023). Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches. Cancers. 15(18). 4622–4622. 9 indexed citations
10.
Salaroglio, Iris C., Fabrizio Tabbò, Sofia La Vecchia, et al.. (2023). Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(19). 3958–3973. 17 indexed citations
11.
Bironzo, Paolo, Luca Primo, Silvia Novello, et al.. (2022). Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response. Clinical Lung Cancer. 23(6). e347–e352. 7 indexed citations
12.
Napoli, Francesca, Ida Rapa, Roberta Libener, et al.. (2022). Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 481(2). 233–244. 2 indexed citations
13.
Tagliamento, Marco, Jordi Remón, Matteo Giaj Levra, et al.. (2022). Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey. JTO Clinical and Research Reports. 4(1). 100446–100446. 3 indexed citations
14.
15.
Perrone, Fabiana, Lorenzo Belluomini, Marco Mazzotta, et al.. (2021). Exploring the role of respiratory microbiome in lung cancer: A systematic review. Critical Reviews in Oncology/Hematology. 164. 103404–103404. 24 indexed citations
16.
Gesmundo, Iacopo, Valentina Audrito, Nicoletta Vitale, et al.. (2019). Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences. 116(6). 2226–2231. 28 indexed citations
17.
Bironzo, Paolo, Daniele Pignataro, Marco Tagliamento, et al.. (2019). P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation. Journal of Thoracic Oncology. 14(10). S713–S713. 5 indexed citations
18.
Tagliamento, Marco, Paolo Bironzo, & Silvia Novello. (2019). New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open. 4(Suppl 3). e000683–e000683. 41 indexed citations
19.
Riganti, Chiara, Iris C. Salaroglio, Chiara Falcomatà, et al.. (2017). Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. OncoImmunology. 7(3). e1398874–e1398874. 34 indexed citations
20.
Schena, Marina, Sara Bustreo, C. Barone, et al.. (2012). Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study.. PubMed. 98(4). 451–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Morena Fasano Breakdown of academic impact, for papers by Mimma Rizzo Breakdown of academic impact, for papers by Umang Swami Breakdown of academic impact, for papers by Sung Hoon Sim Breakdown of academic impact, for papers by Judit Moldvay Breakdown of academic impact, for papers by Deepak Kilari Breakdown of academic impact, for papers by Sander Bins Breakdown of academic impact, for papers by Ion Cotarla Breakdown of academic impact, for papers by Dale R. Shepard Breakdown of academic impact, for papers by Dipesh Uprety
Rankless by CCL
2026